U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H21NO4
Molecular Weight 303.3536
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SCOPOLAMINE

SMILES

CN1[C@]2([H])C[C@]([H])(C[C@@]1([H])[C@@]3([H])[C@]2([H])O3)OC(=O)[C@]([H])(CO)c4ccccc4

InChI

InChIKey=STECJAGHUSJQJN-FWXGHANASA-N
InChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1

HIDE SMILES / InChI

Molecular Formula C17H21NO4
Molecular Weight 303.3536
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 0
Optical Activity UNSPECIFIED

The alkaloid L-(-)-scopolamine [L-(-)-hyoscine], a belladonna alkaloid, competitively inhibits muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, antiemetic, and amnestic effects. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous system, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center. Scopolamine can inhibit the secretion of saliva and sweat, decrease gastrointestinal secretions and motility, cause drowsiness, dilate the pupils, increase heart rate, and depress motor function. Scopolamine is used for premedication in anesthesia and for the prevention of nausea and vomiting (post operative and associated with motion sickness).

Originator

Sources: A. Ladenburg, Ann. 206, 274 (1881); E. Schmidt, Arch. Pharm. 230, 207 (1892).
Curator's Comment:: Scopolamine is an anticholinergic, tropane alkaloid isolated from Datura metel L., Scopola carniolica Jacq. and other Solanaceae. Constituent of impure duboisine from Duboisia myoporoides R. Br., pure duboisine is l-hyoscyamine, q.v. reference retrieved from http://www.drugfuture.com/chemdata/scopolamine.html

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
TRANSDERM SCOP

Approved Use

Transderm Scōp is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with: Motion Sickness and Post Operative Nausea and Vomiting (PONV)

Launch Date

3.15446395E11
Preventing
TRANSDERM SCOP

Approved Use

Transderm Scōp is an anticholinergic agent indicated in adults for the prevention of nausea and vomiting associated with: Motion Sickness and Post Operative Nausea and Vomiting (PONV)

Launch Date

3.15446395E11
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
5 ng/mL
0.5 mg single, intravenous
dose: 0.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SCOPOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2.1 ng × h/mL
1 mg single, topical
dose: 1 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
SCOPOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
369 ng × min/mL
0.5 mg single, intravenous
dose: 0.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SCOPOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
9.5 h
1 mg single, topical
dose: 1 mg
route of administration: Topical
experiment type: SINGLE
co-administered:
SCOPOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
68.7 min
0.5 mg single, intravenous
dose: 0.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SCOPOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
0.5 mg single, intravenous
dose: 0.5 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
SCOPOLAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.4 mg single, intranasal
Highest studied dose
Dose: 0.4 mg
Route: intranasal
Route: single
Dose: 0.4 mg
Sources:
healthy, 21 - 47 years
n = 12
Health Status: healthy
Age Group: 21 - 47 years
Sex: M+F
Population Size: 12
Sources:
Other AEs: Dizziness, Lightheadedness...
Other AEs:
Dizziness (3 patients)
Lightheadedness (3 patients)
Nasal burning (1 patient)
Sources:
0.9 mg 2 times / day multiple, oral
Highest studied dose
Dose: 0.9 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.9 mg, 2 times / day
Sources:
healthy, 21.4 years
n = 35
Health Status: healthy
Age Group: 21.4 years
Sex: M
Population Size: 35
Sources:
Other AEs: Blurred vision, Dizziness...
Other AEs:
Blurred vision
Dizziness
Sources:
6 ug/kg single, intravenous
Dose: 6 ug/kg
Route: intravenous
Route: single
Dose: 6 ug/kg
Sources:
healthy, 22.8 years
n = 9
Health Status: healthy
Age Group: 22.8 years
Sex: M
Population Size: 9
Sources:
1.2 mg single, oral
Highest studied dose
Dose: 1.2 mg
Route: oral
Route: single
Dose: 1.2 mg
Sources:
healthy, 24 years (range: 19-38 years)
n = 12
Health Status: healthy
Age Group: 24 years (range: 19-38 years)
Sex: M
Population Size: 12
Sources:
Other AEs: Dizziness, Dry mouth...
Other AEs:
Dizziness (4 patients)
Dry mouth (3 patients)
Blurred vision (4 patients)
Sources:
10 mg 3 times / day multiple, oral
Overdose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy, 83 years
n = 1
Health Status: unhealthy
Age Group: 83 years
Sex: F
Population Size: 1
Sources:
Other AEs: Consciousness abnormal, Hyperthermia...
Other AEs:
Consciousness abnormal (1 patient)
Hyperthermia (1 patient)
Sources:
0.5 mg single, intravenous
Dose: 0.5 mg
Route: intravenous
Route: single
Dose: 0.5 mg
Sources:
healthy, adult
n = 6
Health Status: healthy
Age Group: adult
Sex: M
Population Size: 6
Sources:
AEs

AEs

AESignificanceDosePopulation
Nasal burning 1 patient
0.4 mg single, intranasal
Highest studied dose
Dose: 0.4 mg
Route: intranasal
Route: single
Dose: 0.4 mg
Sources:
healthy, 21 - 47 years
n = 12
Health Status: healthy
Age Group: 21 - 47 years
Sex: M+F
Population Size: 12
Sources:
Dizziness 3 patients
0.4 mg single, intranasal
Highest studied dose
Dose: 0.4 mg
Route: intranasal
Route: single
Dose: 0.4 mg
Sources:
healthy, 21 - 47 years
n = 12
Health Status: healthy
Age Group: 21 - 47 years
Sex: M+F
Population Size: 12
Sources:
Lightheadedness 3 patients
0.4 mg single, intranasal
Highest studied dose
Dose: 0.4 mg
Route: intranasal
Route: single
Dose: 0.4 mg
Sources:
healthy, 21 - 47 years
n = 12
Health Status: healthy
Age Group: 21 - 47 years
Sex: M+F
Population Size: 12
Sources:
Blurred vision
0.9 mg 2 times / day multiple, oral
Highest studied dose
Dose: 0.9 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.9 mg, 2 times / day
Sources:
healthy, 21.4 years
n = 35
Health Status: healthy
Age Group: 21.4 years
Sex: M
Population Size: 35
Sources:
Dizziness
0.9 mg 2 times / day multiple, oral
Highest studied dose
Dose: 0.9 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.9 mg, 2 times / day
Sources:
healthy, 21.4 years
n = 35
Health Status: healthy
Age Group: 21.4 years
Sex: M
Population Size: 35
Sources:
Dry mouth 3 patients
1.2 mg single, oral
Highest studied dose
Dose: 1.2 mg
Route: oral
Route: single
Dose: 1.2 mg
Sources:
healthy, 24 years (range: 19-38 years)
n = 12
Health Status: healthy
Age Group: 24 years (range: 19-38 years)
Sex: M
Population Size: 12
Sources:
Blurred vision 4 patients
1.2 mg single, oral
Highest studied dose
Dose: 1.2 mg
Route: oral
Route: single
Dose: 1.2 mg
Sources:
healthy, 24 years (range: 19-38 years)
n = 12
Health Status: healthy
Age Group: 24 years (range: 19-38 years)
Sex: M
Population Size: 12
Sources:
Dizziness 4 patients
1.2 mg single, oral
Highest studied dose
Dose: 1.2 mg
Route: oral
Route: single
Dose: 1.2 mg
Sources:
healthy, 24 years (range: 19-38 years)
n = 12
Health Status: healthy
Age Group: 24 years (range: 19-38 years)
Sex: M
Population Size: 12
Sources:
Consciousness abnormal 1 patient
10 mg 3 times / day multiple, oral
Overdose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy, 83 years
n = 1
Health Status: unhealthy
Age Group: 83 years
Sex: F
Population Size: 1
Sources:
Hyperthermia 1 patient
10 mg 3 times / day multiple, oral
Overdose
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources:
unhealthy, 83 years
n = 1
Health Status: unhealthy
Age Group: 83 years
Sex: F
Population Size: 1
Sources:
Overview

Overview

OverviewOther

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes [IC50 119.2 uM]
yes [IC50 217.9 uM]
yes [IC50 540.8 uM]
yes [IC50 6.7 uM]
yes [IC50 699.9 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes (co-administration study)
Comment: The AUC0–24h values of scopolamine were higher during the grapefruit juice period. They reached approximately 142% of the values associated with the control group (water period; P . 0.005)
PubMed

PubMed

TitleDatePubMed
Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs.
1976 Aug
Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine.
1978 Dec
Effects of physostigmine, scopolamine, and mecamylamine on the sleeping time induced by ketamine in the rat.
1979 Mar 14
Behavioral studies of the effects of moderate oligemic hypoxia caused by bilateral clamping of carotid arteries in mice. Impairment of spatial working memory.
1998 Jul-Oct
S 15535, a benzodioxopiperazine acting as presynaptic agonist and postsynaptic 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine.
1999 Nov
Behavioral and memory improving effects of mirtazapine in rats.
1999 Nov-Dec
Effects of histamine H3 receptor agonists and antagonists on cognitive performance and scopolamine-induced amnesia.
1999 Oct
The ameliorating effects of the cognitive-enhancing Chinese herbs on scopolamine-induced amnesia in rats.
2000 Aug
Dehydroevodiamine.HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance.
2000 Jan
Intra-medial prefrontal cortex injections of scopolamine increase instrumental responses for cocaine: an intravenous self-administration study in rats.
2000 Jan 15
Antiamnesic effect of metoprine and of selective histamine H(1) receptor agonists in a modified mouse passive avoidance test.
2000 Jul 7
[Is "scopolamine-induced amnesia" in rats the result of state-dependent learning?].
2000 Mar-Apr
A novel nitrate ester reverses the cognitive impairment caused by scopolamine in the Morris water maze.
2000 Nov 27
Dopaminergic lateralisation in the forebrain: relations to behavioural asymmetries and anxiety in male Wistar rats.
2001
Glucose plus choline improve passive avoidance behaviour and increase hippocampal acetylcholine release in mice.
2001
Muscarinic cholinergic and glutamatergic reciprocal regulation of expression of hippocampal cholinergic neurostimulating peptide precursor protein gene in rat hippocampus.
2001
Effects of MDL 73005 on water-maze performances and locomotor activity in scopolamine-treated rats.
2001 Apr
Neural mechanisms of motion sickness.
2001 Feb
Reversal caused by n-butylidenephthalide from the deficits of inhibitory avoidance performance in rats.
2001 Feb
Long-lasting cholinergic modulation underlies rule learning in rats.
2001 Feb 15
Dehydroevodiamine attenuates beta-amyloid peptide-induced amnesia in mice.
2001 Feb 16
The ameliorating effect of the water layer of Fructus Schisandrae on cycloheximide-induced amnesia in rats: interaction with drugs acting at neurotransmitter receptors.
2001 Jan
Tropane alkaloid production by shoot culture of Duboisia myoporoides R. Br.
2001 Jan
Designing of an orally active complement C3a agonist peptide with anti-analgesic and anti-amnesic activity.
2001 Jan
Scopolamine bioavailability in combined oral and transdermal delivery.
2001 Jan
Developmental exposure to methylmercury alters behavioral sensitivity to D-amphetamine and pentobarbital in adult rats.
2001 Jan-Feb
Occurrence of cadaverine in hairy roots of Brugmansia candida.
2001 Jul
Anti-ischemic and cognition-enhancing properties of NNC-711, a gamma-aminobutyric acid reuptake inhibitor.
2001 Jul 13
Y-27632, an inhibitor of Rho-kinase, antagonizes noradrenergic contractions in the rabbit and human penile corpus cavernosum.
2001 Jun
Dose- and time-dependent scopolamine-induced recovery of an inhibitory avoidance response after its extinction in rats.
2001 Jun
Comparative effects of scopolamine and quinpirole on the striatal fos expression induced by stimulation of D(1) dopamine receptors in the rat.
2001 Mar 2
Subchronic administration of various pretreatments of nerve agent poisoning. II. Compared efficacy against soman toxicity.
2001 May
The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms.
2001 May
The role of muscarinic cholinoceptors in the retrieval of an operant food-related conditioned reflex in cats.
2001 May-Jun
The acetylcholine release enhancer linopirdine induces Fos in neocortex of aged rats.
2001 May-Jun
Substance P and its transglutaminase-synthesized spermine derivative elicit yawning behavior via nitric oxide in rats.
2001 Sep
Patents

Sample Use Guides

Transderm Scōp (scopolamine) transdermal system patch. Each Transderm Scōp patch is formulated to deliver in-vivo approximately 1 mg of scopolamine over 3 days. Initiation of Therapy Motion Sickness To prevent the nausea and vomiting associated with motion sickness, one Transderm Scōp patch (formulated to deliver approximately 1 mg of scopolamine over 3 days) should be applied to the hairless area behind one ear at least 4 hours before the antiemetic effect is required. Post Operative Nausea and Vomiting To prevent post operative nausea and vomiting, one Transderm Scōp patch should be applied the evening before scheduled surgery, except for caesarian section. For caesarian section surgery, to minimize exposure of the newborn baby to the drug, apply the patch one hour prior to caesarian section. Continuation of Therapy Should the patch become displaced, it should be discarded, and a fresh one placed on the hairless area behind the other ear. Motion Sickness If therapy is required for longer than 3 days, the first patch should be removed and a fresh one placed on the hairless area behind the other ear. Post Operative Nausea and Vomiting For perioperative use, the patch should be kept in place for 24 hours following surgery at which time it should be removed and discarded.
Route of Administration: Transdermal
Rosmarinic acid treatment increases the expression of BDNF and GluR-2 proteins and prevents cell death of scopolamine-exposed (300 μM) organotypic hippocampal slice cultures.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:18:27 UTC 2021
Edited
by admin
on Fri Jun 25 21:18:27 UTC 2021
Record UNII
DL48G20X8X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SCOPOLAMINE
HSDB   MI   ORANGE BOOK   VANDF  
Common Name English
HYOSCINE [EP MONOGRAPH]
Common Name English
ATROPINE SULFATE IMPURITY F [EP]
Common Name English
SCOPOLAMINE [MI]
Common Name English
SCOPOLAMINE [ORANGE BOOK]
Common Name English
HYOSCINE [EP]
Common Name English
HYOSCINE
EP   MART.   WHO-DD  
Common Name English
SCOPOLAMINE [VANDF]
Common Name English
BENZENEACETIC ACID, .ALPHA.(HYDROXYMETHYL)-,(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (.ALPHA.S)-
Common Name English
6.BETA.,7.BETA.-EPOXY-1.ALPHA.H,5.ALPHA.H-TROPAN-3.ALPHA.-OL (-)-TROPATE (ESTER)
Common Name English
HYOSCINE [WHO-DD]
Common Name English
BENZENEACETIC ACID, .ALPHA.-(HYDROXYMETHYL)-, 9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL ESTER, (7(S)-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,7.BETA.))-
Common Name English
(1R,2R,4S,5S,7S)-9-METHYL-3-OXA-9-AZATRICYCLO(3.3.1.02,4)NON-7-YL (2S)-3-HYDROXY-2-PHENYLPROPANOATE
Common Name English
HYOSCINE [MART.]
Common Name English
SCOPOLAMINE [USP]
Common Name English
SCOPOLAMINE [HSDB]
Common Name English
Classification Tree Code System Code
WHO-ATC A04AD51
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
WHO-ATC A04AD01
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
WHO-ATC N05CM05
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
CFR 21 CFR 310.533
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
WHO-VATC QA04AD51
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
NDF-RT N0000175574
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
NDF-RT N0000175370
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
WHO-ATC S01FA02
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
WHO-ATC S01BB01
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
LIVERTOX 875
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
WHO-VATC QS01FA02
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
WHO-VATC QN05CM05
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
NCI_THESAURUS C29704
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
WHO-VATC QA04AD01
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
NCI_THESAURUS C29706
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
Code System Code Type Description
DRUG CENTRAL
2424
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
LACTMED
Scopolamine
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
FDA UNII
DL48G20X8X
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
IUPHAR
330
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
EPA CompTox
51-34-3
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
EVMPD
SUB14152MIG
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
WIKIPEDIA
SCOPOLAMINE
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
ChEMBL
CHEMBL1187846
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
DRUG BANK
DB00747
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
NCI_THESAURUS
C47712
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
ECHA (EC/EINECS)
200-090-3
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
MERCK INDEX
M9813
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY Merck Index
RXCUI
9601
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY RxNorm
CAS
51-34-3
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
HSDB
4074
Created by admin on Fri Jun 25 21:18:27 UTC 2021 , Edited by admin on Fri Jun 25 21:18:27 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Related Record Type Details
PRODRUG -> METABOLITE ACTIVE
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC